Phase II trial of carboplatin and vinblastine in advanced squamous-cell carcinoma of the head and neck.
A chemotherapy regimen consisting of carboplatin and vinblastine was given to 30 patients with recurrent or previously untreated, locally advanced squamous carcinoma of the head and neck region. The main aim of the study was to assess the toxicity of this regimen, the feasibility of its outpatient administration and the tumour response. A total of ten patients (33%) achieved an objective response, including two who achieved a complete response. The combination offered useful palliation for patients with recurrent disease; it was well tolerated and can be given on an outpatient basis. This regimen could be combined with other active agents such as methotrexate or bleomycin.
El-Sayed
S
S
Beatson Oncology Centre, Western Infirmary, Glasgow, Scotland, U.K.
Symonds
R P
RP
Robertson
A G
AG
Paul
J
J
McGarva
J
J
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage; D008875:Middle Aged; D012074:Remission Induction; D013997:Time Factors; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D014747:Vinblastine; D016190:Carboplatin; D008787:Metoclopramide